Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
48
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.90 | 28.90 | 0.32% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,649.65 | 400.36 | 1.65% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,727.83 | 2,510.56 | 3.91% |
| NZX 50 Index | 13,345.76 | 143.60 | 1.09% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,802.90 | 29.40 | 0.34% |
| SSE Composite Index | 4,034.59 | 47.58 | 1.19% |